vs

Side-by-side financial comparison of ADTRAN Holdings, Inc. (ADTN) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

ADTRAN Holdings, Inc. is the larger business by last-quarter revenue ($291.6M vs $267.3M, roughly 1.1× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 20.1%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 13.5%).

Adtran, Inc. is an American fiber networking and telecommunications company headquartered in Huntsville, Alabama. It is a vendor of both residential and enterprise networking equipment, along with administrative software for network management and deployment. Its customers include communications service providers, governments, enterprises and utilities.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

ADTN vs ASND — Head-to-Head

Bigger by revenue
ADTN
ADTN
1.1× larger
ADTN
$291.6M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+22.3% gap
ASND
42.3%
20.1%
ADTN
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
13.5%
ADTN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ADTN
ADTN
ASND
ASND
Revenue
$291.6M
$267.3M
Net Profit
$-3.6M
Gross Margin
39.0%
90.5%
Operating Margin
1.5%
Net Margin
-1.2%
Revenue YoY
20.1%
42.3%
Net Profit YoY
92.2%
EPS (diluted)
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADTN
ADTN
ASND
ASND
Q4 25
$291.6M
$267.3M
Q3 25
$279.4M
$230.7M
Q2 25
$265.1M
$170.7M
Q1 25
$247.7M
$109.0M
Q4 24
$242.9M
$187.8M
Q3 24
$227.7M
$62.5M
Q2 24
$226.0M
$38.9M
Q1 24
$226.2M
$103.6M
Net Profit
ADTN
ADTN
ASND
ASND
Q4 25
$-3.6M
Q3 25
$-10.3M
$-65.9M
Q2 25
$-20.5M
$-42.0M
Q1 25
$-11.3M
$-102.2M
Q4 24
$-46.1M
Q3 24
$-33.3M
$-107.1M
Q2 24
$-49.7M
$-118.1M
Q1 24
$-330.8M
$-141.5M
Gross Margin
ADTN
ADTN
ASND
ASND
Q4 25
39.0%
90.5%
Q3 25
38.3%
89.5%
Q2 25
37.3%
80.1%
Q1 25
38.4%
82.6%
Q4 24
36.9%
91.9%
Q3 24
36.5%
80.6%
Q2 24
36.0%
68.2%
Q1 24
31.1%
92.1%
Operating Margin
ADTN
ADTN
ASND
ASND
Q4 25
1.5%
Q3 25
-1.0%
5.1%
Q2 25
-5.0%
-33.5%
Q1 25
-1.6%
-103.2%
Q4 24
-6.9%
Q3 24
-11.5%
-167.3%
Q2 24
-17.0%
-370.2%
Q1 24
-153.1%
-51.2%
Net Margin
ADTN
ADTN
ASND
ASND
Q4 25
-1.2%
Q3 25
-3.7%
-28.5%
Q2 25
-7.7%
-24.6%
Q1 25
-4.5%
-93.7%
Q4 24
-19.0%
Q3 24
-14.6%
-171.5%
Q2 24
-22.0%
-303.9%
Q1 24
-146.2%
-136.6%
EPS (diluted)
ADTN
ADTN
ASND
ASND
Q4 25
$-0.02
Q3 25
$-0.12
Q2 25
$-0.24
Q1 25
$-0.14
Q4 24
$-0.58
Q3 24
$-0.38
Q2 24
$-0.63
Q1 24
$-4.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADTN
ADTN
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$95.7M
$665.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$145.8M
$-175.8M
Total Assets
$1.2B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADTN
ADTN
ASND
ASND
Q4 25
$95.7M
$665.3M
Q3 25
$93.7M
$582.2M
Q2 25
$106.3M
$533.6M
Q1 25
$101.3M
$559.4M
Q4 24
$76.0M
$604.3M
Q3 24
$88.5M
$675.6M
Q2 24
$111.2M
$279.4M
Q1 24
$106.8M
$345.9M
Stockholders' Equity
ADTN
ADTN
ASND
ASND
Q4 25
$145.8M
$-175.8M
Q3 25
$141.6M
$-188.0M
Q2 25
$169.6M
$-202.6M
Q1 25
$138.9M
$-205.0M
Q4 24
$127.0M
$-114.2M
Q3 24
$205.6M
$-105.1M
Q2 24
$213.6M
$-346.8M
Q1 24
$260.8M
$-257.2M
Total Assets
ADTN
ADTN
ASND
ASND
Q4 25
$1.2B
$1.4B
Q3 25
$1.2B
$1.2B
Q2 25
$1.2B
$1.2B
Q1 25
$1.2B
$1.1B
Q4 24
$1.2B
$1.3B
Q3 24
$1.3B
$1.2B
Q2 24
$1.3B
$819.0M
Q1 24
$1.3B
$866.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADTN
ADTN
ASND
ASND
Operating Cash FlowLast quarter
$42.2M
$58.2M
Free Cash FlowOCF − Capex
$30.6M
FCF MarginFCF / Revenue
10.5%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$98.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADTN
ADTN
ASND
ASND
Q4 25
$42.2M
$58.2M
Q3 25
$12.2M
Q2 25
$32.2M
Q1 25
$43.2M
$-15.5M
Q4 24
$2.4M
$-330.7M
Q3 24
$43.3M
Q2 24
$19.9M
Q1 24
$37.9M
$-109.7M
Free Cash Flow
ADTN
ADTN
ASND
ASND
Q4 25
$30.6M
Q3 25
$4.2M
Q2 25
$27.5M
Q1 25
$35.8M
Q4 24
$-895.0K
Q3 24
$37.1M
Q2 24
$8.4M
Q1 24
$24.4M
FCF Margin
ADTN
ADTN
ASND
ASND
Q4 25
10.5%
Q3 25
1.5%
Q2 25
10.4%
Q1 25
14.4%
Q4 24
-0.4%
Q3 24
16.3%
Q2 24
3.7%
Q1 24
10.8%
Capex Intensity
ADTN
ADTN
ASND
ASND
Q4 25
4.0%
Q3 25
2.9%
Q2 25
1.8%
Q1 25
3.0%
Q4 24
1.4%
Q3 24
2.7%
Q2 24
5.1%
Q1 24
6.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADTN
ADTN

Subscriber Solutions$96.2M33%
Optical Networking Solutions$81.8M28%
Access Aggregation Solutions$64.6M22%
Services And Support$48.9M17%

ASND
ASND

Segment breakdown not available.

Related Comparisons